Carbapenem Resistant Pseudomonas aeruginosa Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes

References

• Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22(4):582–610. doi:10.1128/cmr.00040-09
   PubMed Web of Science ®Google Scholar
• HuF, Guo Y, Zhu D, et al. CHINET surveillance of bacterial resistance: results of 2020. Chin J Infect Chemother. 2021;21(4):377–387. doi:10.16718/j.1009-7708.2021.04.001. Chinese.
   Google Scholar
• Strateva T, Yordanov D.Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J Med Microbiol. 2009;58(9):1133–1148. doi:10.1099/jmm.0.009142-0
   Web of Science ®Google Scholar
• Sader HS, Castanheira M, Duncan LR, et al. Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States Medical Centers stratified by infection type: results from the International Network for Optimal Resistance Monitoring (INFORM) surveillance program, 2015–2016. Diagn Microbiol Infect Dis. 2018;92(1):69–74. doi:10.1016/j.diagmicrobio.2018.04.012
   PubMed Web of Science ®Google Scholar
• Walkty A, Lagace-Wiens P, Adam H, et al. Antimicrobial susceptibility of 2906 Pseudomonas aeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: results of the Canadian Ward Surveillance Study (CANWARD), 2008–2015. Diagn Microbiol Infect Dis. 2017;87(1):60–63. doi:10.1016/j.diagmicrobio.2016.10.003
   Web of Science ®Google Scholar
• Lee YL, Ko WC, Hsueh PR. Geographic patterns of carbapenem-resistant Pseudomonas aeruginosa in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2015–2019. Antimicrob Agents CH. 2021;AAC0200021. doi:10.1177/1747493018778713
   Web of Science ®Google Scholar
• Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol. 2011;2:1–13. doi:10.3389/fmicb.2011.00065
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/s1473-3099(17)30753-3
   PubMed Web of Science ®Google Scholar
• Lodise TP, Bassetti M, Ferrer R, et al. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Expert Rev Anti Infect Ther. 2021;12:1–13. doi:10.1080/14787210.2022.2020099
   Web of Science ®Google Scholar
• Hu YY, Cao JM, Yang Q, et al. Risk factors for carbapenem-resistant Pseudomonas aeruginosa, Zhejiang Province, China. Emerg Infect Dis. 2019;25(10):1861–1867. doi:10.3201/eid2510.181699
   PubMed Web of Science ®Google Scholar
• Chen SZ, Xu JJ, Xiao TT, et al. Clinical characteristics and prognostic risk factors analysis of carbapenem-resistant organism in the department of hematology. Chin J Hematol. 2021;42(7):563–569. doi:10.3760/cma.j.issn.0253-2727.2021.07.006. Chinese.
   Google Scholar
• Freire MP, Camargo CH, Yamada AY, et al. Critical points and potential pitfalls of outbreak of IMP-1-producing carbapenem-resistant Pseudomonas aeruginosa among kidney transplant recipients: a case-control study. J Hosp Infect. 2021;115:83–92. doi:10.1016/j.jhin.2021.05.006
   Web of Science ®Google Scholar
• Kang JS, Moon C, SJ Mun, et al. Antimicrobial susceptibility trends and risk factors for antimicrobial resistance in Pseudomonas aeruginosa bacteremia: 12-year experience in a tertiary hospital in Korea. J Korean Med Sci. 2021;36(43):e273. doi:10.3346/jkms.2021.36.e273
   Web of Science ®Google Scholar
• Ministry of Health of the People’s Republic of China. Diagnostic criteria for nosocomial infection (for trial implementation). Natl Med J China. 2001;5:61–67.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne: Clinical and Laboratory Standards Institute; 2020.
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–271. doi:10.1111/j.1469-0691.2011.03570.x
   PubMed Web of Science ®Google Scholar
• Jean SS, Lee YL, Liu PY, et al. Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018. J Microbiol Immunol Infect. 2021;3:1684–1782. doi:10.1016/j.jmii.2021.07.015
   Google Scholar
• Morrow BJ, Pillar CM, Deane J, et al. Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. Diagn Microbiol Infect Dis. 2013;75(4):412–416. doi:10.1016/j.diagmicrobio.2012.12.012
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Y, Zeng J, et al. Risk Factors for Mortality of Inpatients with Pseudomonas aeruginosa Bacteremia in China: Impact ofResistance Profile in the Mortality. Infect Drug Resist. 2020;12(13):4115–4123. doi:10.2147/IDR.S268744
   Web of Science ®Google Scholar
• Lin KY, Lauderdale TL, Wang JT, et al. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: prevalence, risk factors, and impact on outcome of infections. J Microbiol Immunol Infect. 2016;49(1):52–59. doi:10.1016/j.jmii.2014.01.005
   PubMedGoogle Scholar
• Onguru P, Erbay A, Bodur H, et al. Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections. J Korean Med Sci. 2008;23(6):982–987. doi:10.3346/jkms.2008.23.6.982
   Web of Science ®Google Scholar
• Riou M, Carbonnelle S, Avrain L, et al. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents. 2010;36:513–522. doi:10.1016/j.ijantimicag.2010.08.005
   PubMed Web of Science ®Google Scholar
• Lipsitch M, Bergstrom CT, Levin BR. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc Natl Acad Sci. 2000;97(4):1938–1943. doi:10.1073/pnas.97.4.1938
   PubMed Web of Science ®Google Scholar
• da Silva NCZ, da Rocha JA, Do Valle FM, et al. The impact of ageing on the incidence and mortality rate of bloodstream infection: a hospital-based case-cohort study in a tertiary public hospital of Brazil. Trop Med Int Health. 2021;26(10):1276–1284. doi:10.1111/tmi.13650
   PubMed Web of Science ®Google Scholar
• Sacks D, Baxter B, Campbell BCV, et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke. 2018;13(6):612–632. doi:10.1016/j.ccc.2013.03.016
   PubMed Web of Science ®Google Scholar
• Zou Y, Lian J, Di Y, et al. The quick loss of carbapenem susceptibility in Pseudomonas aeruginosa at intensive care units. Int J Clin Pharm. 2018;40(1):175–182. doi:10.1007/s11096-017-0524-5
   Web of Science ®Google Scholar
• Hyle EP, Gasink LB, Linkin DR, et al. Use of different thresholds of prior antimicrobial use in defining exposure: impact on the association between antimicrobial use and antimicrobial resistance. J Infect. 2007;55(5):414–418. doi:10.1016/j.jinf.2007.07.005
   Web of Science ®Google Scholar
• Hirota K, Yoneyama T, Sakamoto M, et al. High prevalence of Pseudomonas aeruginosa from oropharyngeal biofilm in patients with cerebrovascular infarction and dysphagia. Chest. 2010;138(1):237–238. doi:10.1378/chest.10-0240
   Web of Science ®Google Scholar
• Okeng’o K, Chillo P, Gray WK, et al. Early mortality and associated factors among patients with stroke admitted to a large teaching hospital in Tanzania. J Stroke Cerebrovasc Dis. 2016;26(4):871–878. doi:10.1016/j.jstrokecerebrovasdis.2016.10.037
   Web of Science ®Google Scholar
• Leihof RF, Ethelberg S, Nielsen KL, et al. Nosocomial urinary tract infection and risk of bacteraemia in elderly patients: urinary catheter, clinical factors and bacterial species. Infect Dis. 2019;51(7):547–549. doi:10.1080/23744235.2019.1599135
   PubMed Web of Science ®Google Scholar
• Tomczyk S, Zanichelli V, Grayson ML, et al. Control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in healthcare facilities: a Systematic Review and Reanalysis of Quasi-experimental Studies. Clin Infect Dis. 2019;68(5):873–884. doi:10.1093/cid/ciy752
   Web of Science ®Google Scholar
• Kitagawa K, Shigemura K, Yamamichi F, et al. Bacteremia complicating urinary tract infection by Pseudomonas aeruginosa: Mortality risk factors. Int J Urol. 2019;26(3):358–362. doi:10.1111/iju.13872
   Web of Science ®Google Scholar
• Horasan ES, Dağ A, Ersoz G, et al. Surgical site infections and mortality in elderly patients. Med Mal Infect. 2013;43(10):417–422. doi:10.1016/j.medmal.2013.07.009
   Web of Science ®Google Scholar
• Folic MM, Djordjevic Z, Folic N, et al. Epidemiology and risk factors for healthcare-associated infections caused by Pseudomonas aeruginosa. J Chemother. 2020;33(5):294–301. doi:10.1080/1120009x.2020.1823679
   Web of Science ®Google Scholar
• Tsao LH, Hsin CY, Liu HY, et al. Risk factors for healthcare-associated infection caused by carbapenem-resistant. Pseudomonas aeruginosa. J Microbiol Immunol Infect. 2018;51(3):359–366. doi:10.1016/j.jmii.2017.08.015
   Web of Science ®Google Scholar
• Jia H, Li L, Li W, et al. Impact of healthcare-associated infections on length of stay: a Study in 68 Hospitals in China. Biomed Res Int. 2019;2019:2590563. doi:10.1155/2019/2590563
   PubMed Web of Science ®Google Scholar
• Bourgi J, Said JM, Yaakoub C, et al. Bacterial infection profile and predictors among patients admitted to a burn care center: a retrospective study. Burns. 2020;46(8):1968–1976. doi:10.1016/j.burns.2020.05.004
   Web of Science ®Google Scholar
• Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 2005;49(2):760–766. doi:10.1128/aac.49.2.760-766.2005
   PubMed Web of Science ®Google Scholar
• Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008;46(6):862–867. doi:10.1086/528712
   Web of Science ®Google Scholar
• Maeda M, Ozaki T, Yasuoka S, et al. [Role of alveolar macrophages and neutrophils in the defense system against infection of Pseudomonas aeruginosa in the respiratory tract and the effect of derivative of muramyl dipeptide]. Nihon Kyobu Shikkan Gakkai Zasshi. 1990;28(1):135–142. Japanese.
   Google Scholar
• Kamoshida G, Tansho-Nagakawa S, Kikuchi-Ueda T, et al. A novel bacterialtransport mechanism of Acinetobacter baumannii via activated human neutrophils through interleukin-8. J Leukoc Biol. 2016;100(6):1405–1412. doi:10.1189/jlb.4AB0116-023RR
   Web of Science ®Google Scholar